| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pinhas N Dannon, Katherine Lowengrub, I Iancu, Moshe Kotle. Paroxetine in panic disorder: clinical management and long-term follow-up. Expert review of neurotherapeutics. vol 4. issue 2. 2006-04-25. PMID:15853560. |
paroxetine is an example of an selective serotonin reuptake inhibitor agent, which has been well studied in the treatment of panic disorder and is efficacious and well-tolerated. |
2006-04-25 |
2023-08-12 |
Not clear |
| Martin A Katzman, Lukasz Struzik, Lisa L Vivian, Monica Vermani, Joanna C McBrid. Pharmacotherapy of post-traumatic stress disorder: a family practitioners guide to management of the disease. Expert review of neurotherapeutics. vol 5. issue 1. 2006-04-18. PMID:15853483. |
the current evidence-based pharmacologic management approaches to post-traumatic stress disorder, suggests that first-line treatments for monotherapy are the selective serotonin reuptake inhibitors, sertraline, paroxetine and fluoxetine. |
2006-04-18 |
2023-08-12 |
Not clear |
| Shannon K Robinson, Erik S Viirre, Kelly A Bailey, Melissa A Gerke, Jeffery P Harris, Murray B Stei. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosomatic medicine. vol 67. issue 6. 2006-04-11. PMID:16314604. |
to assess the efficacy of a selective serotonin reuptake inhibitor (paroxetine) for relief of tinnitus. |
2006-04-11 |
2023-08-12 |
human |
| Bertrand L Jaber, Luis F Lobon, Nicolaos E Madia. The serotonin syndrome complicating co-prescription of paroxetine and clarithromycin. The American journal of medicine. vol 119. issue 4. 2006-04-10. PMID:16564762. |
the serotonin syndrome complicating co-prescription of paroxetine and clarithromycin. |
2006-04-10 |
2023-08-12 |
Not clear |
| Karl Rickels, Moira Rynn, Malini Iyengar, David Duf. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. The Journal of clinical psychiatry. vol 67. issue 1. 2006-03-28. PMID:16426087. |
paroxetine is a potent selective serotonin reuptake inhibitor with antidepressant and anxiolytic activity that is effective in the treatment of generalized anxiety disorder (gad), improving the core symptoms of anxiety, worry, and tension. |
2006-03-28 |
2023-08-12 |
Not clear |
| Alain Gardie. [Mechanism of action of antidepressant drugs: importance of genetically modified mice in the pharmacological in vivo approach]. Therapie. vol 60. issue 5. 2006-03-28. PMID:16433012. |
in collaborative work we found that genetic (r-nk1 ko mice) or pharmacological (gr205171) blockade of r-nk1 is associated with several changes: the increase in cortical 5-ht outflow caused by systemic injection of paroxetine was 4- to 6-fold higher in freely moving r-nk1 ko mice than in wild-type controls. |
2006-03-28 |
2023-08-12 |
mouse |
| Roberto Mandrioli, Maria A Ragg. Advances in the enantioseparation of second-generation antidepressant drugs by electrodriven methods. Electrophoresis. vol 27. issue 1. 2006-03-17. PMID:16421952. |
in particular, the following pharmacological classes of antidepressants will be considered: selective serotonin reuptake inhibitors (fluoxetine, citalopram, paroxetine, sertraline); norepinephrine reuptake inhibitors (reboxetine); serotonin and norepinephrine reuptake inhibitors (venlafaxine, milnacipran, duloxetine); and noradrenergic and specific serotonergic antidepressants (mirtazapine). |
2006-03-17 |
2023-08-12 |
Not clear |
| Malcolm W Greave. Itch in systemic disease: therapeutic options. Dermatologic therapy. vol 18. issue 4. 2006-03-16. PMID:16297004. |
specifically, the relative merits of broad versus narrowband ultraviolet b (uvb) are discussed and the pros and cons of doxepin, opioid antagonists, and selective serotonin reuptake inhibitors (ssris) such as paroxetine are considered. |
2006-03-16 |
2023-08-12 |
Not clear |
| Sheila V Stager, Karim Calis, Dale Grothe, Meir Bloch, Nannette M Berensen, Paul J Smith, Allen Brau. Treatment with medications affecting dopaminergic and serotonergic mechanisms: effects on fluency and anxiety in persons who stutter. Journal of fluency disorders. vol 30. issue 4. 2006-02-28. PMID:16246409. |
to examine the degree to which each of these two pharmacological mechanisms might independently affect fluency, a selective serotonin reuptake inhibitor, paroxetine, and a selective dopamine (d-2) antagonist, pimozide, were evaluated. |
2006-02-28 |
2023-08-12 |
human |
| N J Langman, C G S Smith, K J Whitehea. Selective serotonin re-uptake inhibition attenuates evoked glutamate release in the dorsal horn of the anaesthetised rat in vivo. Pharmacological research. vol 53. issue 2. 2006-02-27. PMID:16280247. |
co-perfusion of paroxetine (30 microm) with the selective 5-ht(1a) receptor antagonist way 100635 (100 microm) did not prevent the reduction in depolarisation induced glutamate efflux. |
2006-02-27 |
2023-08-12 |
rat |
| P M Llorca, G Brousse, R Schwa. [Escitalopram for treatment of major depressive disorder in adults]. L'Encephale. vol 31. issue 4 Pt 1. 2006-02-24. PMID:16389716. |
this review aimed to compare the efficacy and tolerability of escitalopram versus citalopram and several other ssris (citalopram, fluoxetine, paroxetine, sertraline), and a selective reuptake inhibitor of noradrenaline and serotonin, venlafaxine xr, for treatment of dsm iv (diagnostic and statistical manual of mental disorders - fourth edition) major depressive disorder, based on the studies evaluated by the commission de la transparence de la r6publique frangaise, and data from a pooled analysis presented in 2005 at the 158th annual congress of the american psychiatric association. |
2006-02-24 |
2023-08-12 |
Not clear |
| Emiliano Villa, Claudio Albano, Andrea Cappelli, Emilio Favale, Emilia Fugassa, Ezio Gerdoni, Simona Scarrone, Aroldo Cupell. Is the platelet serotonin transporter different in venous vs. arterial blood? Neurochemical research. vol 30. issue 11. 2006-02-15. PMID:16341932. |
the binding of labelled paroxetine to the serotonin transporter (sert) of platelet membranes has been studied in both venous and mixed venous/arterial blood of the rat. |
2006-02-15 |
2023-08-12 |
rat |
| Kathryn A Chung, Nichole E Carlson, John G Nut. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology. vol 64. issue 10. 2006-02-08. PMID:15911816. |
the authors examined the motor effects of 2 weeks of paroxetine, a serotonin reuptake inhibitor (ssri), and placebo on responses to 2-hour levodopa infusions in 14 subjects with parkinson disease. |
2006-02-08 |
2023-08-12 |
human |
| Giampaolo Perna, Elisa Favaron, Daniela Di Bella, Riccardo Bussi, Laura Bellod. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 12. 2006-01-24. PMID:16034444. |
antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene. |
2006-01-24 |
2023-08-12 |
human |
| Bruno P Guiard, Nicolas Froger, Michel Hamon, Alain M Gardier, Laurence Lanfume. Sustained pharmacological blockade of NK1 substance P receptors causes functional desensitization of dorsal raphe 5-HT 1A autoreceptors in mice. Journal of neurochemistry. vol 95. issue 6. 2006-01-20. PMID:16219031. |
in vivo microdialysis showed that the cortical 5-ht overflow caused by acute injection of the ssri paroxetine (1 mg/kg) was twice as high in gr 205171-treated as in vehicle-treated controls. |
2006-01-20 |
2023-08-12 |
mouse |
| Giampiero Giovacchini, Lixin Lang, Ying Ma, Peter Herscovitch, William C Eckelman, Richard E Carso. Differential effects of paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys. NeuroImage. vol 28. issue 1. 2006-01-11. PMID:15993625. |
we performed pet scans with [(18)f]fpway, an intermediate-affinity antagonist of 5-ht(1a) receptors, in 4 anesthetized rhesus monkeys in control studies and after systemic paroxetine administration (5 mg/kg, i.v.). |
2006-01-11 |
2023-08-12 |
rat |
| Giampiero Giovacchini, Lixin Lang, Ying Ma, Peter Herscovitch, William C Eckelman, Richard E Carso. Differential effects of paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys. NeuroImage. vol 28. issue 1. 2006-01-11. PMID:15993625. |
in addition, a paired [(11)c]dasb study revealed that this paroxetine regimen produced an occupancy of 54-83% of the serotonin transporters. |
2006-01-11 |
2023-08-12 |
rat |
| Tiffany W Cho. Treatment approaches to symptoms associated with frontotemporal degeneration. Current psychiatry reports. vol 7. issue 5. 2006-01-10. PMID:16216158. |
although there is evidence to support a serotonergic deficit, and clinicians frequently prescribe selective serotonin reuptake inhibitors to patients with ftd, only paroxetine and trazodone have been studied. |
2006-01-10 |
2023-08-12 |
Not clear |
| S N Mosolov, E G Kostiukova, A V Gorodnichev, I V Timofee. [Comparative efficacy and tolerability of paroxetine and amitriptiline in long-term therapy preventing depressive recurrences]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 105. issue 10. 2006-01-04. PMID:16281375. |
an open comparative randomized study of paroxetine (selective inhibitor of serotonin re-uptake) and tricyclic antidepressant amitriptiline has been conducted. |
2006-01-04 |
2023-08-12 |
Not clear |
| Zhuo Chen, Julie Tetzlaff, Kumar Sripathirathan, Gonzalo A Carrasco, Mahalakshmi Shankaran, Louis D Van De Kar, Nancy A Muma, George Battagli. Paroxetine is effective in desensitizing 5-HT1A receptor function in adult offspring exposed prenatally to cocaine. Psychopharmacology. vol 180. issue 2. 2005-12-07. PMID:15864558. |
as prenatal cocaine exposure produces long-term deficits in 5-ht neurons in offspring, it may alter the ability of postsynaptic 5-ht(1a) receptors to be desensitized by chronic paroxetine. |
2005-12-07 |
2023-08-12 |
Not clear |